Keywords
Repositioning
Dosage
Antioxidant
Anti-inflammatory
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: Gather evidence and identify scientific approaches that justify the use of ambroxol for other therapeutic purposes. Methods: This was an integrative literature review based on the Medical Literature Analysis and Retrieval System Online (MEDLINE) and Science Direct and Scientific Electronic Library Online (SCIELO). Studies identified by manual search were included. Results: Preliminarily, 162 papers were retrieved, 20 of which were included. Mechanisms of action for ambroxol related to interaction with viral entry proteins were identified; with enzyme repair steps with chaperone function; modulation of ion channels; antioxidant; anti-inflammatory; analgesic; anesthetic and immunomodulatory. Research has associated the use of high doses of ambroxol as a safe possibility for treatment, prevention and/or as an adjuvant in diseases such as COVID-19, Parkinson's, Gaucher, pain relief and as new perspectives of use for the Respiratory System. Final considerations: The repositioning of ambroxol is an advantageous possibility and qualifies as a successful alternative to new therapeutic treatment approaches, where the different mechanisms of action explored by ABX enable it as an alternative for combined use with other therapies.
References
ALKOTAJI M. Azithromycin and ambroxol as potential pharmacotherapy for SARS-CoV-2. International journal of antimicrobial agents, 2020; 56(6):106192.
ARMSTRONG MJ, OKUN MS. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA, 2020; 323(6):548-560.
BAR BI, et al. Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase. Blood Cells Mol Dis.,2013; 50(2):141-5
BARAKA AM, EL-HADIDY F. Role of ambroxol as a prophylactic agent against COVID-19. Universal Journal of Pharmaceutical Research., 2021; 6(1):61-65
BOUSCARY A. Drug repositioning in neurodegeneration: An overview of the use of ambroxol in neurodegenerative diseases. European Journal of Pharmacology, 2020; 884:173446.
CAI L, et al. Drug repositioning based on the heterogeneous information fusion graph convolutional network. Brief Bioinform, 2021; 22(6):bbab319.
CAZAN D, et al. Safety of ambroxol in the treatment of airway diseases in adult patients. Expert opinion on drug safety, 2018; 17(12):1211-1224.
CHENOT JF, et al. Efficacy of Ambroxol lozenges for pharyngitis: a meta-analysis. BMC Family Practice, 2014; 13; 15:45.
DE MEY C, et al. Efficacy and Safety of Ambroxol Lozenges in the Treatment of Acute Uncomplicated Sore Throat–a Pooled Analysis. Drug Research, 2016; 66(7):384-92.
FATIMA S, et al. Repurposing Immunomodulatory Drugs to Combat Tuberculosis. Frontier Immunology, 2021; 13; 12:645485.
GAIDA W, et al. Ambroxol, a Nav1.8-preferring Na (+) channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain. Neuropharmacology, 2005; 49(8):1220-7.
KEHINDE I A, et al. Inhibitory mechanism of Ambroxol and Bromhexine Hydrochlorides as potent blockers of molecular interaction between SARS-CoV-2 spike protein and human angiotensin-converting Enzyme-2. Journal of Molecular Graphics and Modelling, 2022; 114:108201
KERN KU, WEISER T. Topical ambroxol for the treatment of neuropathic pain. An initial clinical observation. Der Schmerz, 2015; 29 Suppl 3(Suppl 3):S89-96.
KHOURY T, et al. A synergistic effect of Ambroxol and Beta-Glucosylceramide in alleviating immune-mediated hepatitis: A novel immunomodulatory non-immunosuppressive formulation for treatment of immune-mediated disorders. Biomed Pharmacother, 2020; 132:110890.
KIM YM, et al. Pharmacologic properties of high-dose ambroxol in four patients with Gaucher disease and myoclonic epilepsy. J Med Genet, 2020; 57(2):124-131.
LIPPI G, et al. COVID-19: unravelling the clinical progression of nature’s virtually perfect biological weapon. Annals of translational medicine, 2020; eight (11):693.
MCNEILL a et al. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain, 2014; 137(Pt 5):1481-95.
MITINI-NKHOMA SC. et al. Ion Transport Modulators Differentially Modulate Inflammatory Responses in THP-1-Derived Macrophages. Journal of immunology research., 2021; 2021: 8832586
MULLIN S, et al. Ambroxol for the Treatment of Patients with Parkinson Disease with and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial. JAMA Neurol., 2020; 1; 77(4):427-434.
OLALEYE OA, et al. Ambroxol hydrochloride inhibits the interaction between severe acute respiratory syndrome coronavirus 2 spike protein’s receptor binding domain and recombinant human ACE2. BioRxiv, 2020; 14:2020.09.13.295691.
PFEIFER S, et al. Reduction of cytokine release of blood and bronchoalveolar mononuclear cells by ambroxol. European journal of medical research,1997; 24; 2(3): 129-32
PINHEIRO DCSN, et al. Atividade imunomoduladora das plantas medicinais: perspectivas em medicina veterinária, Ciência animal, 2003; 13(1): 23-32.
PITCAIRN C, et al. Dysregulation of the autophagic-lysosomal pathway in Gaucher and Parkinson's disease. Neurobiology of disease, 2019; 122: 72-82.
PUSHPAKOM S, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov., 2019; 18(1): 41-58.
RATJEN F, et al. A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis. European journal of pediatrics.1985; 374-378
REFAI M, et al. Short-term perioperative treatment with ambroxol reduces pulmonary complications and hospital costs after pulmonary lobectomy: a randomized trial. European journal of cardio-thoracic surgery, 2009; 35(3):469-73.
SILVEIRA CRA, et al. Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double blind, placebo-controlled trial. BMC Neurol., 2019; 9; 19(1): 20.
TANG H, et al. The application of ambroxol hydrochloride combined with fiberoptic bronchoscopy in elderly patients with severe pneumonia: A meta-analysis and systematic review. Medicine, 2022; 28-101(4): e28535.
VAN DRIEL ML, et al. Are sore throat patients who hope for antibiotics actually asking for pain relief?.The Annals of Family Medicine, 2006; 4(6):494-9.
WANG Yu, et al. Sputum characteristics and airway clearance methods in patients with severe COVID-19. Medicine, 2020; 13; 99(46): e23257.
WAUER RR, et al. Randomized double blind trial of Ambroxol for the treatment of respiratory distress syndrome. European journal of pediatrics, 1992; 151(5):357-63
WU X, et al. Meta‐analysis of high doses of ambroxol treatment for acute lung injury/acute respiratory distress syndrome based on randomized controlled trials. The Journal of Clinical Pharmacology, 2014; 54(11):1199-206.
XIA DH, et al. The protective effects of ambroxol on radiation lung injury and influence on production of transforming growth factor β1 and tumor necrosis factor α. Medical Oncology, 2010; 27(3): 697-701.
ZHANG H, et al. Antenatal maternal medication administration in preventing respiratory distress syndrome of premature infants: A network meta‐analysis. The Clinical Respiratory Journal, 2018; 12(10): 2480-2490.
ZHANG ZQ, et al. Prevention of respiratory distress syndrome in preterm infants by antenatal ambroxol: a meta-analysis of randomized controlled trials. American journal of perinatology, 2013; 30(7): 529-36.
ZIMRAN A, et al. Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease. Blood Cells, Molecules, and Diseases, 2013; 50(2): 134-7.